Novartis options Heptares’ Star GPCR tech in $200m deal
Novartis has optioned rights to apply Heptares Therapeutics’ Star GPCR technology to one of its drug development programmes in a deal that, the UK firm says, could be worth over $200m.
Archives for October 12, 2009
Elections to ISPE's board and a Roche exec joining Dendreon's board – People on the move
in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including elections to ISPE's board and a Roche exec joining Dendreon's board.
AAIPharma Inc becomes ZeeCRO
US contract clinical services provider AAIPharma Inc has change its name ZeeCRO.